SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. was incorporated in 1995 and is headquartered in New York, New York.…
SIGA Technologies Inc (SIGA) (Q3 2026) Earnings Call Highlights: New Canada Contract, $116 ...
SIGA Technologies (NASDAQ: SIGA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 2.400 USD on 20 November 2026, down 58.5% over 52 weeks. Its 52-week range is 2.300 USD to 7.110 USD: the price is 66.2% below the high and 4.3% above the low.
At a market capitalisation of 172.45M USD, it trades at 240.0 times trailing earnings and 5.5 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 880% for SIGA.
SIGA Technologies reports return on equity of 11.7%, an operating margin of -14.2% and revenue down 49.7% year over year.
It holds more cash than debt, a net cash position of 116.11M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. The next earnings report is expected on 9 March 2027.